Company overview Financial review 2022 priorities Appendix References 1 Investor Relations │ Q3 2022 Results û Q3 2022 Results Investor presentation U NOVARTIS | Reimagining Medicine Company overview Financial review 2022 priorities Appendix References 2 NOVARTIS Q3 RESULTS | OCTOBER 25, 2022 | NOVARTIS INVESTOR PRESENTATION Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identifi ...